Outcomes of patients with multiple cutaneous squamous cell carcinomas

Michael W. Pelster, Jeffrey D Wayne, Simon S Yoo*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

IMPORTANCE Patients with multiple cutaneous squamous cell carcinomas(CSCCs)poseamanagementchallengeforphysicians, but their prognosis isunknownbecauseoutcomeshave notbeen compared between patientswhoformsingle vs multipleCSCCs. OBJECTIVE To compare outcomes in patients with 1 vs multiple CSCCs. DESIGN, SETTING, AND PARTICIPANTS A 10-year retrospective single-institution cohort study at an academic tertiary care center of patients with dermally invasive (non-in situ) primary CSCC diagnosed from January 1, 2000, through December 31, 2009. MAIN OUTCOMES AND MEASURES Electronic medical records were reviewed to determine the tumor stage (Brigham and Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death due to CSCC). Outcomes were compared between patients with 1 vs more than 1 CSCC via multivariable competing-risk regression adjusted for other significant cofactors. RESULTS Of 985 patients with CSCC, 727 had 1 CSCC, 239 had 2 to 9 CSCCs, and 19 had 10 or more CSCCs. Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9%]). The median follow-up time was 50 months (range, 2-142 months). Patients with more than 1 CSCC had a higher risk of LR (subhazard ratio for 2-9 CSCCs, 1.8; 95%CI, 1.1-4.3; and for ≥10 CSCCs, 3.8; 95%CI, 1.4-10.0) and NM (subhazard ratio for 2-9 CSCCs, 3.0; 95%CI, 1.4-6.5; and for ≥10 CSCCs, 4.2; 95%CI, 1.4-10.4) compared with patients with 1 CSCC, adjusted for Brigham andWomen's Hospital tumor stage. The 10-year cumulative incidence of LR and NM was higher in patients with 2 to 9 CSCCs and markedly higher in those with 10 or more CSCCs compared with patients who had 1 CSCC (10-year cumulative incidence for 1 CSCC: LR, 3.0%; 95%CI, 2.0%-4.5%; and NM, 2.3%; 95% CI, 1.5%-3.8%; for 2-9 CSCCs: LR, 6.7%; 95%CI, 4.2%-10.6%; and NM, 5.9%; 95%CI, 3.5%-9.6%; and for ≥10 CSCCs: LR, 36.8%; 95%CI, 19.2%-59.0%; and NM, 26.3%; 95%CI, 11.8%-48.8%). CONCLUSIONS AND RELEVANCE Patients with multiple CSCCs warrant frequent follow-up because they have an elevated risk of LR and NM. In particular, patients with 10 or more CSCCs have markedly elevated risks of recurrence and metastasis.

Original languageEnglish (US)
Pages (from-to)130-131
Number of pages2
JournalJAMA oncology
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Squamous Cell Carcinoma
Skin
Neoplasm Metastasis
Recurrence
Neoplasms
Electronic Health Records
antineoplaston A10
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{76460ea7a18741a2b6f44e62e6be013d,
title = "Outcomes of patients with multiple cutaneous squamous cell carcinomas",
abstract = "IMPORTANCE Patients with multiple cutaneous squamous cell carcinomas(CSCCs)poseamanagementchallengeforphysicians, but their prognosis isunknownbecauseoutcomeshave notbeen compared between patientswhoformsingle vs multipleCSCCs. OBJECTIVE To compare outcomes in patients with 1 vs multiple CSCCs. DESIGN, SETTING, AND PARTICIPANTS A 10-year retrospective single-institution cohort study at an academic tertiary care center of patients with dermally invasive (non-in situ) primary CSCC diagnosed from January 1, 2000, through December 31, 2009. MAIN OUTCOMES AND MEASURES Electronic medical records were reviewed to determine the tumor stage (Brigham and Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death due to CSCC). Outcomes were compared between patients with 1 vs more than 1 CSCC via multivariable competing-risk regression adjusted for other significant cofactors. RESULTS Of 985 patients with CSCC, 727 had 1 CSCC, 239 had 2 to 9 CSCCs, and 19 had 10 or more CSCCs. Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9{\%}]). The median follow-up time was 50 months (range, 2-142 months). Patients with more than 1 CSCC had a higher risk of LR (subhazard ratio for 2-9 CSCCs, 1.8; 95{\%}CI, 1.1-4.3; and for ≥10 CSCCs, 3.8; 95{\%}CI, 1.4-10.0) and NM (subhazard ratio for 2-9 CSCCs, 3.0; 95{\%}CI, 1.4-6.5; and for ≥10 CSCCs, 4.2; 95{\%}CI, 1.4-10.4) compared with patients with 1 CSCC, adjusted for Brigham andWomen's Hospital tumor stage. The 10-year cumulative incidence of LR and NM was higher in patients with 2 to 9 CSCCs and markedly higher in those with 10 or more CSCCs compared with patients who had 1 CSCC (10-year cumulative incidence for 1 CSCC: LR, 3.0{\%}; 95{\%}CI, 2.0{\%}-4.5{\%}; and NM, 2.3{\%}; 95{\%} CI, 1.5{\%}-3.8{\%}; for 2-9 CSCCs: LR, 6.7{\%}; 95{\%}CI, 4.2{\%}-10.6{\%}; and NM, 5.9{\%}; 95{\%}CI, 3.5{\%}-9.6{\%}; and for ≥10 CSCCs: LR, 36.8{\%}; 95{\%}CI, 19.2{\%}-59.0{\%}; and NM, 26.3{\%}; 95{\%}CI, 11.8{\%}-48.8{\%}). CONCLUSIONS AND RELEVANCE Patients with multiple CSCCs warrant frequent follow-up because they have an elevated risk of LR and NM. In particular, patients with 10 or more CSCCs have markedly elevated risks of recurrence and metastasis.",
author = "Pelster, {Michael W.} and Wayne, {Jeffrey D} and Yoo, {Simon S}",
year = "2016",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2015.3894",
language = "English (US)",
volume = "2",
pages = "130--131",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "1",

}

Outcomes of patients with multiple cutaneous squamous cell carcinomas. / Pelster, Michael W.; Wayne, Jeffrey D; Yoo, Simon S.

In: JAMA oncology, Vol. 2, No. 1, 01.01.2016, p. 130-131.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Outcomes of patients with multiple cutaneous squamous cell carcinomas

AU - Pelster, Michael W.

AU - Wayne, Jeffrey D

AU - Yoo, Simon S

PY - 2016/1/1

Y1 - 2016/1/1

N2 - IMPORTANCE Patients with multiple cutaneous squamous cell carcinomas(CSCCs)poseamanagementchallengeforphysicians, but their prognosis isunknownbecauseoutcomeshave notbeen compared between patientswhoformsingle vs multipleCSCCs. OBJECTIVE To compare outcomes in patients with 1 vs multiple CSCCs. DESIGN, SETTING, AND PARTICIPANTS A 10-year retrospective single-institution cohort study at an academic tertiary care center of patients with dermally invasive (non-in situ) primary CSCC diagnosed from January 1, 2000, through December 31, 2009. MAIN OUTCOMES AND MEASURES Electronic medical records were reviewed to determine the tumor stage (Brigham and Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death due to CSCC). Outcomes were compared between patients with 1 vs more than 1 CSCC via multivariable competing-risk regression adjusted for other significant cofactors. RESULTS Of 985 patients with CSCC, 727 had 1 CSCC, 239 had 2 to 9 CSCCs, and 19 had 10 or more CSCCs. Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9%]). The median follow-up time was 50 months (range, 2-142 months). Patients with more than 1 CSCC had a higher risk of LR (subhazard ratio for 2-9 CSCCs, 1.8; 95%CI, 1.1-4.3; and for ≥10 CSCCs, 3.8; 95%CI, 1.4-10.0) and NM (subhazard ratio for 2-9 CSCCs, 3.0; 95%CI, 1.4-6.5; and for ≥10 CSCCs, 4.2; 95%CI, 1.4-10.4) compared with patients with 1 CSCC, adjusted for Brigham andWomen's Hospital tumor stage. The 10-year cumulative incidence of LR and NM was higher in patients with 2 to 9 CSCCs and markedly higher in those with 10 or more CSCCs compared with patients who had 1 CSCC (10-year cumulative incidence for 1 CSCC: LR, 3.0%; 95%CI, 2.0%-4.5%; and NM, 2.3%; 95% CI, 1.5%-3.8%; for 2-9 CSCCs: LR, 6.7%; 95%CI, 4.2%-10.6%; and NM, 5.9%; 95%CI, 3.5%-9.6%; and for ≥10 CSCCs: LR, 36.8%; 95%CI, 19.2%-59.0%; and NM, 26.3%; 95%CI, 11.8%-48.8%). CONCLUSIONS AND RELEVANCE Patients with multiple CSCCs warrant frequent follow-up because they have an elevated risk of LR and NM. In particular, patients with 10 or more CSCCs have markedly elevated risks of recurrence and metastasis.

AB - IMPORTANCE Patients with multiple cutaneous squamous cell carcinomas(CSCCs)poseamanagementchallengeforphysicians, but their prognosis isunknownbecauseoutcomeshave notbeen compared between patientswhoformsingle vs multipleCSCCs. OBJECTIVE To compare outcomes in patients with 1 vs multiple CSCCs. DESIGN, SETTING, AND PARTICIPANTS A 10-year retrospective single-institution cohort study at an academic tertiary care center of patients with dermally invasive (non-in situ) primary CSCC diagnosed from January 1, 2000, through December 31, 2009. MAIN OUTCOMES AND MEASURES Electronic medical records were reviewed to determine the tumor stage (Brigham and Women's Hospital tumor stage) and outcomes (local recurrence [LR], nodal metastases [NM], and death due to CSCC). Outcomes were compared between patients with 1 vs more than 1 CSCC via multivariable competing-risk regression adjusted for other significant cofactors. RESULTS Of 985 patients with CSCC, 727 had 1 CSCC, 239 had 2 to 9 CSCCs, and 19 had 10 or more CSCCs. Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9%]). The median follow-up time was 50 months (range, 2-142 months). Patients with more than 1 CSCC had a higher risk of LR (subhazard ratio for 2-9 CSCCs, 1.8; 95%CI, 1.1-4.3; and for ≥10 CSCCs, 3.8; 95%CI, 1.4-10.0) and NM (subhazard ratio for 2-9 CSCCs, 3.0; 95%CI, 1.4-6.5; and for ≥10 CSCCs, 4.2; 95%CI, 1.4-10.4) compared with patients with 1 CSCC, adjusted for Brigham andWomen's Hospital tumor stage. The 10-year cumulative incidence of LR and NM was higher in patients with 2 to 9 CSCCs and markedly higher in those with 10 or more CSCCs compared with patients who had 1 CSCC (10-year cumulative incidence for 1 CSCC: LR, 3.0%; 95%CI, 2.0%-4.5%; and NM, 2.3%; 95% CI, 1.5%-3.8%; for 2-9 CSCCs: LR, 6.7%; 95%CI, 4.2%-10.6%; and NM, 5.9%; 95%CI, 3.5%-9.6%; and for ≥10 CSCCs: LR, 36.8%; 95%CI, 19.2%-59.0%; and NM, 26.3%; 95%CI, 11.8%-48.8%). CONCLUSIONS AND RELEVANCE Patients with multiple CSCCs warrant frequent follow-up because they have an elevated risk of LR and NM. In particular, patients with 10 or more CSCCs have markedly elevated risks of recurrence and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84973411456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973411456&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2015.3894

DO - 10.1001/jamaoncol.2015.3894

M3 - Review article

VL - 2

SP - 130

EP - 131

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 1

ER -